ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0775

A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings
Abstract Number: 0776

Follicular Dendritic Cell PD-L1 Expression Promotes Autoreactive Germinal Center Formation
Abstract Number: 0777

Rheumatoid Factor B Cell Clones Proliferate Predominantly as Atypical Memory B Cells in Reactive Cervical Lymph Node Follicles Compared to Extrafollicular Sites in Affected Salivary Glands of SjS Patients
Abstract Number: 0778

Comprehensive Immune Profiling of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Patients with Autoimmune Disease
Abstract Number: 0779

Sex Differences in the B Cell Compartment of Patients with Oligoarticular Juvenile Idiopathic Arthritis
Abstract Number: 0780

Deep B Cell Tissue Depletion Following Anti-CD19 CART Cells Therapy
Abstract Number: 0781

An Expanded Cytotoxic CD8 T Cell Population Regulated by CD155-CD226 in SSc-ILD
Abstract Number: 0782

30-Color Full Spectrum Flow Cytometry Identifies Sex Differences in the Circulating Immune Landscape of Systemic Sclerosis
Abstract Number: 0783

Spatial Reconstruction of Interstitial Lung Disease
Abstract Number: 0784

RUNX1 Is Expressed in a Subpopulation of Dermal Fibroblasts and Is Increased with Systemic Sclerosis Disease Severity
Abstract Number: 0785

Exploring the Link Between Atgl-Dependent Lipolysis and Dermal Fibrosis in Systemic Sclerosis
Abstract Number: 0786

First Analyses of Transcriptomic Changes in the Skin of SSc Patients upon CD19-targeting CAR T Cell Therapy
Abstract Number: 0787

Efficacy of Intra-Articular Hyaluronic Acid Injection for Nonsurgical Management of Carpometacarpal Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Abstract Number: 0788

Long-term Effectiveness of a Lifestyle Intervention for Osteoarthritis: Two-year Follow-up After the “Plants for Joints” Randomized Clinical Trial
Abstract Number: 0789

An Online Trial to Assess the Efficacy and Safety of a Supplement Combination in People with Hand Osteoarthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].